Align Technology, Inc. has announced the appointment of Paul Clancy and Ian Bell to its Board of Directors, a strategic move aimed at bolstering the company’s leadership as it navigates the competitive landscape of the orthopedic and surgical appliance industry.
On November 17, 2026, the Board appointed Clancy, a seasoned biopharmaceutical executive, effective immediately, while Bell, the Chief Operating Officer of Alcon, will join the Board on December 10, 2026. This decision increases the Board's size from 11 to 13 directors, reflecting Align's commitment to enhancing its governance and operational oversight.
Kevin Conroy, Chairman of the Board, expressed enthusiasm about the new appointments, stating, “Paul and Ian bring significant global healthcare, financial, innovation and operational leadership experience that will complement the strengths of Align’s Board.” He highlighted Clancy’s extensive background in financial strategy and Bell’s operational expertise as invaluable assets to the company’s growth trajectory.
Background
Align Technology, Inc. operates in the orthopedic, prosthetic, and surgical appliances and supplies sector, specifically focusing on designing and manufacturing the Invisalign System, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry. The company is publicly traded on the Nasdaq under the ticker symbol ALGN and has a CIK of 0001097149.
What the Filing Says
The recent SEC filing states, “On November 17, 2026, the Board of Directors of Align Technology, Inc. appointed Paul Clancy to the Board, effective immediately, and Ian Bell to the Board, effective December 10, 2026.” The filing also notes that both new directors will participate in the company’s compensation program for non-employee directors.
Impact
These appointments may positively impact Align Technology’s strategic direction and operational efficiency. Clancy’s background includes significant roles at Alexion Pharmaceuticals and Biogen, where he honed his financial leadership skills, while Bell’s experience at Alcon and other companies brings a wealth of operational knowledge. Their combined expertise is expected to enhance the company’s decision-making processes and strategic initiatives.
What's Next
Both Clancy and Bell are expected to stand for election at Align Technology’s next annual meeting of stockholders, scheduled for May 2027. The filing does not specify any further actions following their appointments.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










